Global Oral Drug Delivery Market Trends and Insights
Chronic Disease and Polypharmacy Expansion
Chronic noncommunicable disease remains a core source of demand for the oral drug delivery market. The World Health Organization projects that the population aged 60 years and older will increase from 1.1 billion in 2023 to 1.4 billion by 2030. Older patients often need several medicines for cardiovascular disease, diabetes, central nervous system conditions, and other long-term illnesses. Oral formats allow these patients to follow a regular treatment routine without arranging repeated clinical visits. Fixed dose combinations can reduce the number of separate products that patients need to take each day. This makes tablets and capsules particularly relevant for long-term treatment plans that must balance treatment adherence with routine care.Polypharmacy also changes the formulation requirements placed on the oral drug delivery market. Patients using several medicines may benefit from modified-release products that simplify daily dosing. Combination products can support treatment adherence when clinicians need to manage more than 1 condition at the same time. The need is most visible in aging populations in North America, Europe, Japan, and South Korea. Daily oral treatment remains practical for hypertension, lipid management, anticoagulation, and many other common conditions. The resulting prescription base creates stable demand for established oral forms while supporting the development of products designed for more complex care routines.
Patient Preference for Convenient, Noninvasive Administration
Oral administration gives many patients a familiar option that does not require needles or scheduled infusion visits. This preference supports home-based treatment for chronic conditions that require regular and long-duration use. It also supports telehealth and digital pharmacy models, where prescribing, education, and refill services can be coordinated outside traditional care sites. The oral drug delivery market benefits when a therapy can move from supervised initiation to routine self-administration. Convenience is especially relevant for patients who require frequent treatment or who have limited ability to travel to specialist centers. The practical value of self-administration helps explain why home care was the largest end-user setting in 2025.The same preference is shaping the way manufacturers position differentiated oral products. Orally disintegrating tablets, oral films, and mini tablets can help patients with swallowing difficulties or complicated treatment routines. These formats can also give companies a way to distinguish a medicine from a conventional tablet when the active ingredient is otherwise familiar. Noninvasive delivery does not remove the need for clinical monitoring in high acuity conditions. It can, however, reduce the time and logistical burden associated with routine dosing. This creates a clear reason for developers to consider patient handling and dosing experience during formulation design.
Gastrointestinal Degradation, Bioavailability, and Product Design Limits
Gastrointestinal degradation limits the number of macromolecules that can currently be developed as oral products. A 2026 scientific review reported that 90% to 99% of ingested protein can be degraded before it reaches the absorptive epithelium. The same review noted that most biologics have oral bioavailability below 1% under physiological conditions. Oral semaglutide shows that commercial peptide products are possible, but it also requires controlled fasting use and a permeation enhancer. These limits reduce the number of injectable medicines that can readily move into oral formats. They place a premium on formulation methods that protect the active ingredient and improve absorption without affecting safety.Product design introduces further limits for orally disintegrating tablets and films. High active ingredient loading can make a format larger, less palatable, or less stable. Taste masking becomes important when a product dissolves in the mouth and exposes the patient directly to the active ingredient. Developers must also generate evidence that a new oral format delivers consistent exposure and meets chemistry, manufacturing, and control requirements. This can slow the progress of products that appear technically promising at an early stage. The constraint is particularly relevant for pediatric and geriatric uses, where a patient-friendly format must still deliver a reliable therapeutic dose.
Other drivers and restraints analyzed in the report include:
- Oral Biologics and Peptide Pipeline Expansion
- Patent Cliff Lifecycle Reformulation
- Excipient, Nitrosamine, and Quality Documentation Requirements
Segment Analysis
Tablets held 52.4% of global revenue in 2025, making them the leading dosage form. Their position reflects wide use in cardiovascular, central nervous system, and anti-infective treatments. Tablets can accommodate a broad range of active ingredient loads and release profiles. Manufacturers can also produce them efficiently through established compression, coating, and packaging systems. Matrix, bilayer, and coated tablets give formulators several routes to modify release behavior. Fixed-dose combination tablets are particularly relevant for patients who take several long-term medicines. Powders, granules, liquids, syrups, lozenges, and other forms remain important where swallowing or dissolution constraints limit conventional tablets. These formats serve pediatric, geriatric, and specialized therapeutic uses. The oral drug delivery market, therefore, relies on tablets for scale while maintaining a broader mix of administration options.Capsules are forecast to grow at a 7.5% CAGR through 2031, the fastest pace among dosage forms. Their growth reflects value in lipid-based delivery systems for poorly soluble molecules. Capsules can also support multiparticulate and modified release designs. Sprinkle capsules provide an option for patients who cannot swallow a conventional solid dosage form. Research published in 2026 described a growing role for amorphous solid dispersions and lipid-based formulations in enabling oral delivery of poorly water-soluble drugs. Capsule formats can house these systems during both clinical and commercial development. They can also support premium products where performance depends on formulation complexity. The faster growth of capsules does not displace tablets. It instead reflects a need for formats that handle difficult molecules and more specialized dosing requirements.
Cardiovascular disorders accounted for 28.5% of the oral drug delivery market size in 2025. The segment depends on a large population of patients requiring regular treatment for hypertension, lipid disorders, and anticoagulation. These therapies are often designed for unsupervised use over long periods. Daily oral dosing makes it possible to manage treatment in home care settings. Statins, antihypertensives, and anticoagulants have also created deep prescribing familiarity with oral formats. This base supports the stable use of tablets and capsules across many health systems. The segment remains important even as newer medicines require more complex formulation work. It provides a large established demand pool for lifecycle management and differentiated dosage forms. The oral drug delivery industry continues to serve this therapeutic area through both conventional and newer products.
Oncology is projected to grow at an 8.2% CAGR through 2031. Oral targeted therapies can reduce dependence on infusion center visits for selected treatment regimens. Targeted kinase inhibitors, PARP inhibitors, and oral immunomodulatory agents are important areas of development. These products require careful management because dosing, toxicity, adherence, and drug interactions may need close clinical oversight. Oral oncology can therefore start in a structured care setting before longer-term treatment shifts toward the patient’s home. High-potency active ingredient handling also affects the manufacturing choices available to sponsors. This supports investment in contained development and production facilities. The segment’s growth reflects both patient convenience and the ongoing shift toward targeted treatment approaches. It also increases the need for quality, packaging, and pharmacy support that is appropriate for high acuity medicines.
Complete Report Scope:
- By Dosage Form
- Tablets
- Capsules
- Powders and Granules
- Liquids and Syrups
- Lozenges and Pastilles
- Other Dosage Forms
- By Therapeutic Area
- Cardiovascular Disorders
- Central Nervous System Disorders
- Oncology
- Diabetes and Obesity
- Gastrointestinal Disorders
- Infectious Diseases
- Pain Management
- Other Therapeutic Areas
- By Application
- Disease Treatment
- Preventive and Prophylactic Use
- Research and Academic Purposes
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online and Specialty Pharmacies
- By End User
- Home-Care Settings
- Hospitals and Specialty Clinics
- Long-Term Care Facilities
- Other End Users
- Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 41.3% of global revenue in 2025. The region benefits from substantial pharmaceutical research activity, broad payer coverage for innovative products, and a dense network of development and manufacturing providers. The United States has been an early launch market for new oral metabolic therapies, oral peptide programs, and specialty oral medicines. It also has established prescription, specialty pharmacy, and direct delivery channels that can support new products. Catalent, Thermo Fisher Scientific, Piramal Pharma Solutions, and other specialists contribute to the region’s development and production capacity. These capabilities can support a medicine from formulation work through commercial supply. North America remains important because it combines innovative product demand with technical manufacturing depth. This supports its leading position in the oral drug delivery market.Europe is the second-largest regional market and has strong quality standards and consolidated healthcare systems. These systems encourage cost-effective oral generics in primary care while also supporting complex medicines through specialist pathways. Germany, France, the United Kingdom, and the Nordic countries remain important innovation markets. Spain, Italy, and Portugal contribute significant generic manufacturing capacity. Recipharm invested in high-potency oral solid-dose capabilities at its Leganés facility in Spain for Phase 3 oncology and orphan programs. The investment reflects regional interest in more complex oral manufacturing. Novo Nordisk reported that the United Kingdom approved the Wegovy pill in June 2026 after the FDA and UAE approvals. South America remains smaller, although Brazil supports regional growth through generic medicine use and local oral solid dose production.
Asia Pacific is projected to grow at a 6.4% CAGR through 2031. Rising chronic disease prevalence, broader healthcare access, generic medicine adoption, and manufacturing investment all support growth across the region. China and India are the principal growth markets. China’s localization policies are supporting domestic pharmaceutical capacity, while India remains a large exporter of generic tablets and capsules. Japan has a sophisticated oral pharmaceutical sector that emphasizes controlled-release and modified-release products for cardiovascular and central nervous system conditions. Regional growth also creates opportunities for companies that can meet local regulatory needs and scale supply efficiently. The Middle East and Africa are emerging regions where access and insurance coverage are expanding in several Gulf countries. This geographic pattern gives the oral drug delivery market a combination of high-value mature demand and expanding volume demand. It also broadens the oral drug delivery market’s manufacturing base.
List of Companies Covered in this Report:
- Novo Nordisk
- Pfizer
- Novartis
- Merck
- Sanofi
- AstraZeneca
- Eli Lilly and Company
- Abbvie
- Takeda Pharmaceuticals
- Roche
- GlaxoSmithKline
- Catalent
- Lonza Group
- Thermo Fisher Scientific
- Recipharm
- Aenova Group GmbH
- Piramal Group
- Aquestive Therapeutics
- Intelgenx
- ZIM Laboratories
- Evonik Industries
- C.L. Pharm Co., Ltd.
- Indivior
- Dr. Reddy’s Laboratories
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novo Nordisk A/S
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- Sanofi
- AstraZeneca PLC
- Eli Lilly and Company
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- F. Hoffmann-La Roche Ltd
- GSK plc
- Catalent, Inc.
- Lonza Group Ltd
- Thermo Fisher Scientific Inc.
- Recipharm AB
- Aenova Group GmbH
- Piramal Pharma Solutions
- Aquestive Therapeutics, Inc.
- IntelGenx Corp.
- ZIM Laboratories Limited
- Evonik Industries AG
- C.L. Pharm Co., Ltd.
- Indivior PLC
- Dr. Reddy's Laboratories Limited

